Morgan Stanley initiated coverage on shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) in a research note released on Thursday morning, The Fly reports. The firm issued an overweight rating on the stock.
Separately, ValuEngine raised shares of ASTELLAS PHARMA/ADR from a strong sell rating to a sell rating in a research note on Tuesday, December 3rd.
Shares of ALPMY opened at $17.41 on Thursday. The firm has a 50-day simple moving average of $17.14 and a two-hundred day simple moving average of $15.45. ASTELLAS PHARMA/ADR has a 1-year low of $12.77 and a 1-year high of $17.50. The stock has a market cap of $32.77 billion, a PE ratio of 16.42 and a beta of 0.77.
About ASTELLAS PHARMA/ADR
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.
Featured Article: What is a Swap?
Receive News & Ratings for ASTELLAS PHARMA/ADR Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com’s FREE daily email newsletter.
